Research Topics
Genomes and Genes | Ariel MillerSummaryAffiliation: Technion-Israel Institute of Technology Country: Israel Publications
| Collaborators
|
Detail Information
Publications
Vitamin B12, demyelination, remyelination and repair in multiple sclerosisAriel Miller
Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Haifa 34362, Israel
J Neurol Sci 233:93-7. 2005....- Health-related quality of life in multiple sclerosis: psychometric analysis of inventoriesAriel Miller
Neuroimmunology Unit and Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel
Mult Scler 11:450-8. 2005..The aim was to gain insight into HRQoL as viewed by Israeli multiple sclerosis (MS) patients, with an eye to its cross-cultural applicability, using psychometric analysis and a regression-based procedure... - Multiple sclerosis: from basic immunopathology to immune interventionAriel Miller
Neuroimmunology Research Unit, Carmel Medical Center, Rappaport Institute for Research in the Medical Sciences and Faculty of Medicine, Technion - Isreal Institute of Technology, Haifa 34362, Israel
Clin Neurol Neurosurg 104:172-6. 2002 - Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affectAriel Miller
Center for Multiple Sclerosis, Carmel Medical Center, Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
J Neurol Sci 259:67-73. 2007..In addition, clinical studies pertaining to the safety and efficacy of DM/Q in a variety of neurological disease states are ongoing... - Pseudobulbar affect in multiple sclerosis: toward the development of innovative therapeutic strategiesAriel Miller
Center for Multiple Sclerosis, Department of Neurology, Carmel Medical Center, Rappaport Faculty of Medicine and Research Institute, Technion, Haifa, Israel
J Neurol Sci 245:153-9. 2006..When administered in a fixed combination with quinidine, dextromethorphan is effective in treating PBA in patients with ALS, and preliminary results suggest that this therapy also is effective in treating MS-related PBA... 
Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatmentsAriel Miller
Technion Israel Institute of Technology, Carmel Medical Center, Department of Neurology, 7 Michal St, Haifa 34362, Israel
Expert Rev Neurother 11:1077-88. 2011..As life expectancy lengthens and the neurologic settings of PBA become more common, the need for treatment can be expected to increase...- Translation towards personalized medicine in Multiple SclerosisAriel Miller
Multiple Sclerosis and Brain Research Center, Carmel Medical Center, Israel
J Neurol Sci 274:68-75. 2008..In light of the rapid advances in technology and progress in applying individualized treatment strategies in other diseases, 'Personalized Medicine' for MS seems feasible within the coming years... - Bio-markers of disease activity and response to therapy in multiple sclerosisAriel Miller
Division of Neuroimmunology and Multiple Sclerosis Center, Rappaport Institute for Research in the Medical Sciences, Faculty of Medicine, Technion-Israel Institute of Technology, 7 Michal Street, Haifa 34362, Israel
Clin Neurol Neurosurg 106:249-54. 2004 - Health-related quality of life in multiple sclerosis: The impact of disability, gender and employment statusAriel Miller
Multiple Sclerosis Center, Carmel Medical Center, Technion Israel Institute of Technology, Haifa, Israel
Qual Life Res 15:259-71. 2006.... - Patients with multiple sclerosis in a war zone: coping strategies associated with reduced risk for relapseEli Somer
Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel
Mult Scler 16:463-71. 2010..Further research should explore whether the employment of specific ways of coping can reduce the risk for relapse among patients with multiple sclerosis during periods of distress... - Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosisDana Haves-Zburof
Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
J Cell Mol Med 15:2421-9. 2011.... - Cytokine-mediated modulation of MMPs and TIMPs in multipotential neural precursor cellsTamir Ben-Hur
Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel
J Neuroimmunol 175:12-8. 2006..IFN-beta, on the other hand, appears to have an anti-proteolytic influence that may attenuate such NPC-mediated repair processes... - Auditory feedback control for improvement of gait in patients with Multiple SclerosisYoram Baram
Department of Computer Science, Technion Israel Institute of Technology, Haifa, Israel
J Neurol Sci 254:90-4. 2007..To study the use of auditory feedback for gait management and rehabilitation in patients with Multiple Sclerosis (MS)... - Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesisDoron Melamed
Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
Int Immunol 18:1355-62. 2006..We conclude that B lymphocyte development is accompanied with MMP-9 secretion and the developing cells are competent to modify this secretion upon different immune stimuli... - Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affectGuy Haiman
Department of Neurology, Carmel Medical Center, Technion Israel Institute of Technology, Haifa, Israel
J Clin Psychopharmacol 29:444-52. 2009..In conclusion, differences in brain activity were observed before and after medication. Also, DM/Q administration resulted in normalization of behavioral and electrophysiological measures... - Immunological indicators of disease activity and prognosis in multiple sclerosisYanina Galboiz
Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Rappaport Institute for Research in the Medical Sciences, Technion-Israel Institute of Technology, 7 Michal Street, Haifa 34362, Israel
Curr Opin Neurol 15:233-7. 2002..Recent studies focusing on the identification of possible immunological markers in multiple sclerosis will be reviewed... - The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-betaSarah Shapiro
Immunology Research Unit, Carmel Medical Center, 7 Michal Street, Haifa 34362, Israel
J Neuroimmunol 144:116-24. 2003..These results confirm IFN-mediated modulation of the APC surface within the immunological-synapse and implicate CD80 and CD86 as targets for interventional therapies in MS as well as other Th1-mediated autoimmune diseases... - The ubiquitin-proteasome pathway regulates claudin 5 degradationIlana Mandel
Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
J Cell Biochem 113:2415-23. 2012.... - Hypoxia of endothelial cells leads to MMP-2-dependent survival and deathYaara Ben-Yosef
Immunology Research Unit, Carmel Medical Center, 7 Michal St, Haifa 34362, Israel
Am J Physiol Cell Physiol 289:C1321-31. 2005..Hence, in the hypoxic microenvironment, MMP-2 appears to have a dual autocrine role in determining the fate of ECs... - Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: implications to multiple sclerosisYanina Galboiz
Neuroimmunology Unit, Department of Neurology, Carmel Medical Center, 7 Michal Street, Haifa, Israel
J Neuroimmunol 131:191-200. 2002.... - Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitisSarah Shapiro
Immunology Research Unit, Lady Davis Carmel Medical Center, 7 Michal Street, Haifa, 34362 Israel
J Neurol Sci 206:43-8. 2003.... - Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapsesLea Glass-Marmor
Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
J Neuroimmunol 210:124-7. 2009..These findings provide preliminary characterization of biomarkers in the application of chronobiology-based glucocorticoid therapeutics in MS and other immune disorders... - Multiple sclerosis in diverse populations: characteristics in distinct Arab ethnicities in IsraelMichal Siegel
Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Israel
Mult Scler 18:1737-44. 2012..Multiple sclerosis (MS) prevalence and genetic susceptibility varies among the different ethnic groups of Jews and Arabs in Israel... - Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosisElias Toubi
Rappaport Faculty of Medicine, Technion Israel Institute of Technology, 31096 Haifa, Israel
J Neuroimmunol 251:45-54. 2012..These findings shed additional light on the mechanisms underlying the effects of laquinimod in MS and potentially other immune-mediated diseases... - Tight junction proteins expression and modulation in immune cells and multiple sclerosisIlana Mandel
Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
J Cell Mol Med 16:765-75. 2012.... - Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosisLena Melamud
Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel
J Neurol Sci 314:37-40. 2012..The role of melatonin in MS-related sleep disturbances and fatigue as well as the interaction between melatonin and Interferon beta (IFN-β) treatment were the subject of this study... - Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affectGuy Haiman
Multiple Sclerosis and Brain Research Czenter, Department of Neurology, Carmel Medical Center, Haifa, Israel
J Neurol Sci 271:137-47. 2008..To characterize the brain activity and associated cortical structures involved in pseudobulbar affect (PBA), a condition characterized by uncontrollable episodes of emotional lability in patients with multiple sclerosis (MS)... - Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cellsMichal Abraham
Neuroimmunology Research Unit, Carmel Medical Center, Haifa, Israel
J Neuroimmunol 163:157-64. 2005.... - The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cellsMichal Abraham
Neuroimmunology and Immunology Research Units, Carmel Medical Center, and Rappaport Institute for Research in the Medical Sciences, and Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
Int Immunol 14:1449-57. 2002.... - Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markersIris Grossman
Division of Neuroimmunology and Multiple Sclerosis Center, Rappaport Faculty of Medicine and Research Institute, Technion and Carmel Medical Center, Haifa, Israel
Pharmacogenet Genomics 17:657-66. 2007..These findings provide additional progress toward development of pharmacogenetics-based personalized treatment for multiple sclerosis... - Telemedicine for multiple sclerosis patients: assessment using Health Value CompassKeren Zissman
Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
Mult Scler 18:472-80. 2012..Telemedicine carries the potential of improving accessibility to health services, especially for disabled people... - Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: modulation by interferon-β and role played in cell migrationElsebeth Staun-Ram
Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
J Neuroimmunol 232:200-6. 2011..These findings support further studies in the importance of Cathepsins and Cystatins in immunomodulation... 
Chronotherapy using corticosteroids for multiple sclerosis relapsesLea Glass Marmor
Division of Neuroimmunology, Multiple Sclerosis Center, Carmel Medical Center, 7 Michal Street, Haifa 34362, Israel
J Neurol Neurosurg Psychiatry 78:886-8. 2007..In diseases characterised by aberrant immune activity, chronotherapy (a treatment regimen tailored to diurnal body rhythms) may increase the efficiency, safety and tolerability of drugs...- Glide-symmetric locomotion reinforcement in patients with multiple sclerosis by visual feedbackYoram Baram
Department of Computer Science, Technion Israel Institute of Technology, Technion City, Haifa, Israel
Disabil Rehabil Assist Technol 5:323-6. 2010.... - Aberrant expression of the apoptosis-related proteins BAK and MCL1 in T cells in multiple sclerosisIlana Mandel
Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Carmel Medical Center, Haifa, Israel
J Neuroimmunol 244:51-6. 2012..Concomitantly, the expression levels of the pro-apoptotic protein BAK were decreased in MS patients at relapse. These findings suggest the dysregulation of the apoptosis-related proteins MCL1 and BAK in MS... - Impact of exposure to war stress on exacerbations of multiple sclerosisDaniel Golan
Multiple Sclerosis Center and Department of Neurology, Carmel Medical Center, Haifa, Israel
Ann Neurol 64:143-8. 2008..To assess the relation between stress caused by the perils of rocket attack on civilian centers in northern Israel during the 2006 war between Hezbollah and Israel and multiple sclerosis (MS) exacerbations... - Internet usage by patients with multiple sclerosis: implications to participatory medicine and personalized healthcareIzabella Lejbkowicz
Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, P O Box 9649, Haifa 31096, Israel
Mult Scler Int 2010:640749. 2010..This paper suggests that MS patients benefit from online information, and it emphasizes the importance of resources tailored to patients needs... - Cognitive strategies application of multiple sclerosis patientsSmadar Birnboim
The Center of Multiple Sclerosis and Brain Research, Carmel Medical Center, Haifa, Israel
Mult Scler 10:67-73. 2004.... - Detection of multiple sclerosis from exhaled breath using bilayers of polycyclic aromatic hydrocarbons and single-wall carbon nanotubesRadu Ionescu
Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion, Israel Institute of Technology, Haifa 32000, Israel
ACS Chem Neurosci 2:687-93. 2011..The results could serve also as a launching pad for the discrimination between different subphases or stages of multiple sclerosis as well as for the identification of multiple sclerosis patients who would respond well to immunotherapy... - Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosisIzabella Lejbkowicz
Pharmacogenetics and Translational Genetics Center, Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
Expert Rev Neurother 12:343-52. 2012.... - Emotional responses of children and adolescents to parents with multiple sclerosisRivka Yahav
Faculty of Social Welfare and Health Studies, School of Social Work, University of Haifa, Haifa, Israel
Mult Scler 11:464-8. 2005..We consider the interaction between the sex of the parent and the sex of the child in connection with these feelings and discuss the implications of the 'parental child' role of these children... - Virtual reality cues for improvement of gait in patients with multiple sclerosisYoram Baram
Department of Computer Science, Technion Israel Institute of Technology, Haifa, Israel
Neurology 66:178-81. 2006..To study the effects of visual cues, provided through a portable visual-feedback virtual reality (VR) apparatus, on the walking abilities of patients with multiple sclerosis (MS)... - Matrix metalloproteinase-9, its tissue inhibitor(TIMP)-1 and CRP in Alzheimer's diseaseMichael Inspector
Neuroimmunology Unit, Carmel Medical Center, Haifa, Israel
Eur Neurol 53:155-7. 2005 - Inorganic lead enhances cytokine-induced elevation of matrix metalloproteinase MMP-9 expression in glial cellsNitza Lahat
Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
J Neuroimmunol 132:123-8. 2002..These results demonstrate a possible new mechanism by which Pb may induce neuropathological processes... - Neuroimmunology in Israel--2002: proceedings of the 2nd annual meeting of the Israel society of neuroimmunologyDimitrios Karussis
Department of Neurology, Hadassah Medical Center, Jerusalem, Israel
J Neuroimmunol 131:1-4. 2002 - Sexual dysfunction in females with multiple sclerosis: quantitative sensory testingIlan Gruenwald
Neuro urology unit, Rambam Medical Center, Haifa, Israel
Mult Scler 13:95-105. 2007..Quantitative sensory testing (QST) has recently been used to assess normal neural function of the female genitalia. In this study we used QST for assessment of the genital neural function of female MS patients... - Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseasesEyal Ben-Ami
Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
Autoimmun Rev 10:410-5. 2011.... - Emerging therapeutic targets in multiple sclerosisPaulo Fontoura
Department of Immunology, Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal
Curr Opin Neurol 19:260-6. 2006..Implementation of these facilitates identification of new targets for therapy towards tailoring treatment to the individual patient with multiple sclerosis... - Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosisHillel S Panitch
Neurology Health Care Service, Fletcher Allen Health Care, University of Vermont, Burlington, 05401, USA
Ann Neurol 59:780-7. 2006.... - Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trialF Fazekas
Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, A 8036 Graz, Austria
Neurology 71:265-71. 2008..We therefore set out to test two different doses of a new formulation of immunoglobulin termed IGIV-C 10% for suppression of both clinical and MRI disease activity as well as safety... - In vitro induction of regulatory T cells by anti-CD3 antibody in humansMichal Abraham
Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
J Autoimmun 30:21-8. 2008..Thus, we have identified human T cells with strong in vitro regulatory properties induced in vitro by anti-CD3 which appear to act in a non-HLA restricted fashion by affecting antigen presenting cells... - Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosisDouglas S Goodin
Department of Neurology, University of California, San Francisco, CA 94121, USA Email
Curr Med Res Opin 23:2823-32. 2007.... - Multiple sclerosis frequency in Israel's diverse populationsMilton Alter
Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
Neurology 66:1061-6. 2006..CONCLUSION: Diverse ethnic groups living in the same geographic area may have significantly different frequencies of MS... - Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosisMikael Schwarz
Glycominds Ltd, Lod 71291, Israel
J Neurol Sci 244:59-68. 2006..0001). The present findings support further assessment of serum anti-Galpha4Galpha antibodies as a potential biomarker for MS, which may confirm disease diagnosis and aid in its management...